Drug Development Drug Pricing Pharmaceutical Companies 
STAT
DECEMBER 19, 2024
Access to cheaper alternatives and low enrollment prompted the company to remove the medicine — along with the HIV medicines Emtriva, Tybost, and Complera — from its patent assistance program next month, according to an Oct. 8 letter that announced the move and that has not been widely reported.
STAT
DECEMBER 13, 2024
Just 9% came from the private sector, such as pharmaceutical companies. Looked at another way, the public sector provided 62% of the $1.2 billion in funding, followed by philanthropies that contributed 24%. Continue to STAT+ to read the full story…
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Express Pharma
JULY 27, 2024
On one hand, robust IPR protection is essential to incentivise research and development. It encourages pharmaceutical companies to invest heavily in discovering new drugs, developing innovative treatments, and improving healthcare outcomes. However, the flip side of the coin is equally important.
Pharmaceutical Technology
MAY 17, 2023
The Inflation Reduction Act, which became US law in August 2022, has invited its fair share of critics and supporters over its drug pricing provisions. While negotiating drug prices is common practice in other major markets, CMS had not previously held the legal authority to do so.
Pharmaceutical Technology
JUNE 29, 2022
Almost 40 years since it was instituted, some have described the FDA’s orphan drug program, which is meant to foster innovation, as “ one of the most successful US legislative actions in recent history ”. However, extended market exclusivity is often associated with high drug pricing and limited patient access.
pharmaphorum
AUGUST 27, 2020
Over the past five to ten years US investors have focused on technology and internet companies, and relatively little on new biotech or pharmaceutical companies.
European Pharmaceutical Review
OCTOBER 19, 2022
Patents are often described as the ‘lifeblood’ of pharmaceutical companies. 1 However, patent protection for pharmaceutical products is an economic trade-off between providing monopoly rights that incentivise development of future products and permitting higher drug prices to recoup the investment.
Expert insights. Personalized for you.
206 
Let's personalize your content